Vascular endothelial growth factor expressing mesenchymal stem cells improves cardiac function in chronic myocardial infarction in pigs

Transplantation of mesenchymal stem cells （MSCs） for myocardial reconstruction has shown promise in both animal models and human phase 1 clinical studies. Vascular endothelial growth factor （VEGF） is a strong therapeutic agent for treating ischaemia by inducing angiogenesis. The feasibility of ex vivo MSCs mediated gene transfer is documented. Matsumoto and colleagues have recently reported genetically engineered MSCs carrying VEGF165 delivery for revascularization in a model of acute myocardial infarction （MI）. The promising data from our laboratory in both angiogenesis and MSCs transplantation in cunicular heart model of acute MI have prompted us to attempt the combined and simultaneous application of the two strategies.     

控制危险因素加强缺血性脑卒中的防治

中国卫生部2007年统计信息显示,导致中国公众死亡的疾病中,脑血管病排在第一位.脑卒中是脑血管病最常见类型,其中缺血性脑卒中占所有脑卒中的80%～85%. 缺血性卒中的病因(发病机制)主要有2种,一种为微栓子,如心源性、动脉源性及反常栓子;另一种为血流动力学异常,最常见的原因是动脉粥样硬化导致动脉狭窄(≥70%)甚至梗阻,其远端脑灌注量下降.其他少见病因包括:血管痉挛、机械压迫等.     

几种为Authorware制作的CAI课件节省磁盘空间的方法

文章结合实践介绍了在应用Authorware制作CAI课件时,通过采用对媒体素材的压缩、程序方面的压缩和文件发布及安装时的压缩等操作,使课件“减肥”,以达到节省磁盘空间的几种措施和方法。     

含罂粟壳中成药质量标准分析

罂粟壳属于麻醉药品管理。目前已上市的部分中成药处方中含有罂粟壳,针对罂粟壳使用的特殊要求,我们对含罂粟壳中成药质量标准进行了分析,对存在的问题进行了探讨。     

模拟生物矿化制备多糖铁的新方法

目的建立模拟生物矿化制备多糖铁的新方法.方法选用壳聚糖,与FeCl3制成复合膜,模拟铁矿化过程,制备多糖铁.结果多糖铁为β-FeOOH晶形,且为纳米级.结论为开发补铁药提供了新途径,丰富和发展了纳米药学理论.     

注重基本技能训练提高学生临床实践能力

对临床教学面临的困难及开展基本技能的必要性的进行了思考.结合自身通过遴选临床教学主讲老师,加强师资队伍的培训;建设多功能临床模拟实验室;加强基本功训练,提高学生临床动手能力等方式,开展了临床技能优化训练,并取得了一定的成效.     

Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer.

PURPOSE: Tumor necrosis treatment (TNT) uses degenerating tumor cells and necrotic regions of tumors as targets for radioimmunotherapy. Previous studies in animal tumor models and clinical trials have demonstrated that when linked to the therapeutic radionuclide iodine-131, recombinant chimeric TNT antibody ((131)I-chTNT) can deliver therapeutic doses to tumors regardless of the location or type of malignancy. Therapeutic efficacy and toxicity of (131)I-chTNT in advanced lung cancer patients were studied in this pivotal registration trial. PATIENTS AND METHODS: Patients with advanced lung cancer were treated with systemic or intratumoral injection of (131)I-chTNT in eight oncology centers in China. The objective response rate (ORR) was assessed as the primary end point. RESULTS: All 107 patients who were entered onto the study and completed therapy had experienced treatment failure after prior radiotherapy or chemotherapy a mean of three times. The results showed an ORR of 34.6% (complete response, 3.7%; partial response, 30.8%; no change, 55.1%; and progressive disease, 10.3%) in all patients and 33% in 97 non-small-cell lung cancer patients. A biodistribution study demonstrated excellent localization of the radioactivity in tumors in both systemically and intratumorally injected patients. The most obvious adverse side effect was mild and reversible bone marrow suppression. CONCLUSION: Radioimmunotherapy with (131)I-chTNT was well tolerated and can be used systemically or locally to treat refractory tumors of the lung.     

原发性乳腺鳞状细胞癌临床病理分析

回顾性分析11例原发性乳腺鳞状细胞癌（primary squamous cell careinoma of the breast,PSCCB）患者的临床病理资料.11例均行手术治疗,术后病理检查4例发生腋窝淋巴结转移,生存超过5年的7例,3例死于肿瘤复发和转移.回顾性研究的结果提示,PSCCB患者的临床表现与普通类型的乳腺癌比较无特异性,确诊需依据病理诊断,由于其发病率低,规范的治疗和预后评价有待进一步研究.     

Immuntherapie maligner Non-Hodgkin-Lymphome

Zusammenfassung Auch wenn in den vergangenen Jahren z. T. eine Verbesserung der Prognose von Non-Hodgkin-Lymphomen (NHL) bereits mit veränderten konventionellen und eskalierten Chemotherapieverfahren indolenter und aggressiver Lymphome erreicht werden konnte, verläuft für einen großen Teil der Patienten die Tumorerkrankung noch immer fatal. Da eine weitere Optimierung konventioneller Modalitäten schwer möglich erschien, stellte die Etablierung immuntherapeutischer Ansätze eine attraktive Option dar. Die erfolgreiche Einführung monoklonaler Antikörper in die Behandlung maligner Lymphome hat die Immuntherapie fest etabliert. Weiterentwicklungen dieses passiven Immuntherapieansatzes sind auf dem Weg in den klinischen Alltag. Daneben sind unterschiedliche Verfahren aktiver Immunisierung (Vakzinierung) in präklinischen und frühen klinischen Entwicklungen, deren Etablierung eine weitere Bereicherung des therapeutischen Armentariums darstellen kann. Zuletzt hat — insbesondere für Hochrisikopatienten — die allogene Stammzelltransplantation in der jüngsten Vergangenheit an Attraktivität gewonnen.     

p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.

PURPOSE: Recent studies have highlighted that the p53 codon 72 polymorphism plays a crucial role in modulating wild-type p53 apoptotic capacity, and as such may influence the response to chemotherapy. Thus, the purpose of this study was to investigate whether the p53 codon 72 polymorphism might influence pathologic response to neoadjuvant chemotherapy in primary breast cancer. EXPERIMENTAL DESIGN: One hundred and ten operable breast cancer patients received anthracycline-based neoadjuvant chemotherapy and p53 codon 72 polymorphism status was analyzed by PCR-RFLP. RESULTS: The distribution of initial clinical stage, tumor size, estrogen receptor or progesterone receptor status, menopausal status, or erbB2 expression was not significantly different among the polymorphic variants. However, we found that only 13% (3 of 23) of patients with the Pro/Pro variant had a good pathologic response, defined as a complete pathologic response or minimal residual disease. In comparison, 40% (22 of 55) or 37.5% (12 of 32) of patients with the Pro/Arg or Arg/Arg variant had a good pathologic response (P = 0.019). Moreover, patients with the Pro/Pro variant were more likely to have a positive axillary lymph node status than those with the Pro/Arg or Arg/Arg variant (P = 0.007). Furthermore, in multivariate analysis, p53 codon 72 polymorphism was found to be a strong predictor of pathologic response (odds ratio 6.7, 95% confidence interval, 1.4-31.2; P = 0.016). CONCLUSION: Our study indicates that breast cancer patients with the Pro/Pro variant may be less sensitive to anthracycline-based treatment than those with the Pro/Arg or Arg/Arg variant and suggests that analysis of p53 codon 72 polymorphism may provide a simple predictive marker for selecting the right breast cancer patients to anthracycline-based neoadjuvant chemotherapy in clinical setting.